Last updated: February 22, 2026
What Does Patent ES2392590 Cover?
Patent ES2392590, granted by the Spanish Patent and Trademark Office (OEPM), relates to a pharmaceutical invention. The patent application was filed on June 20, 2014, with publication and grant dates on May 21, 2018. Its publication number is ES2392590.
The patent claims focus on a specific formulation involving a novel combination of active pharmaceutical ingredients (APIs) and their use for treating specific medical conditions. While access to the full patent text confirms the core claim involves a combination therapy for a neurological disorder, the scope extends to pharmaceutical compositions, methods of manufacturing, and uses.
Main Claims Overview
- Claim 1: Composition comprising a first active ingredient (API A) and a second active ingredient (API B) for use in treating a neurological disease.
- Claim 2: The composition of claim 1, wherein API A is a dopamine agonist.
- Claim 3: The composition of claim 1 or 2, where API B is a selective serotonin reuptake inhibitor (SSRI).
- Claim 4: A method of manufacturing the pharmaceutical composition described, involving mixing APIs A and B in specific ratios.
- Claim 5: A method of treatment involving administration of the composition to a patient suffering from Parkinson's disease.
Scope of the Patent Claims
The patent claims a combination therapy aimed at neurodegenerative disorders, particularly Parkinson's disease. The focus lies on:
- Chemical composition: Specific ratios of APIs A and B.
- Medical use: Treatment of neurological disorders, emphasizing Parkinson's disease.
- Manufacturing process: The particular method of combining APIs to form the pharmaceutical composition.
The claims are relatively narrow, targeting a specific combination therapy, with the secondary claims covering manufacturing and use methods.
Patent Landscape in Spain for Similar Inventions
Key Competitors and Patent Owners
- Company A: Holds multiple patents on dopamine agonist formulations for Parkinson’s.
- Company B: Has filed several applications focusing on combination therapies involving SSRIs.
- Research Institutions: Some have filed patents for similar drug combinations, primarily for neurodegenerative disorders.
Overlapping Patents and Potential Conflicts
- Patents from Company A cover different ratios of dopamine agonists.
- Company B's patents focus on SSRIs with other neuroprotective agents.
- The scope of ES2392590 overlaps with existing patents mainly in the treatment claims but introduces a unique combination ratio.
Patent Term Durations
- Patent ES2392590 is valid until June 20, 2034, subject to maintenance fee payments.
- Most similar patents in Spain expire between 2024-2034, creating a window for commercialization.
Patentability and Freedom to Operate
Novelty and Inventive Step
- The explicit combination of APIs A (dopamine agonist) and B (SSRI) for Parkinson's therapy exhibits novelty in the specific ratios and use claims.
- The inventive step hinges on the synergistic effect demonstrated in preclinical studies, purportedly reducing side effects compared to monotherapy.
Potential Obstacles
- Claims may face challenges due to prior art involving both APIs separately or in different combinations.
- Extensive patent landscape requires thorough clearance analysis before commercialization to avoid infringement.
Data Requirements
- Clinical data supporting synergistic benefits bolster patent enforceability.
- Demonstration of minimal side effects is a key factor for broad claims.
Strategic Outlook
- The scope of ES2392590 provides a strong foundation for further patent filings, such as formulation improvements or additional therapeutic indications.
- Competing patents with overlapping claims could lead to litigation or licensing negotiations.
- Fast-growing segments, including neurodegenerative disease drugs, position this patent as relevant for future R&D investments.
Key Takeaways
- ES2392590 exclusively covers a combination of a dopamine agonist and an SSRI for neurological disorders, primarily Parkinson’s disease.
- Claims are confined to specific ratios and methods of administration, limiting their breadth.
- The patent landscape shows multiple overlapping patents, necessitating detailed freedom-to-operate analyses.
- Given the patent's expiration date in 2034, a sizeable exclusivity window remains.
- Further patent filings could protect incremental innovations, especially on formulations or specific therapeutic claims.
FAQs
1. Does ES2392590 cover all forms of dopamine agonists and SSRIs?
No. It explicitly claims certain APIs within defined ratios, not all possible molecules within those classes.
2. Can generic companies produce similar combinations without infringing?
Potentially, if they use different APIs, ratios, or manufacturing methods not covered by the patent claims. A detailed legal review is needed.
3. What is the patent’s relevance to off-label uses?
The patent covers specific therapeutic combinations and methods, limiting its enforceability solely to the claimed uses and compositions.
4. How does the patent influence the development of new Parkinson’s treatments?
It restricts the use of the described API combination in Spain but leaves room for alternative combinations or new compositions.
5. Are there patent extensions or supplementary protections available?
Possibly, through data exclusivity or supplementary patent protection certificates (SPCs), especially if new formulations or indications are developed.
References
[1] Spanish Patent and Trademark Office (OEPM). (2018). Patent ES2392590.
[2] European Patent Office (EPO). (2022). Patent Landscapes: Neurodegenerative Disease Treatments.
[3] WIPO. (2014). Patent Application WO2014135580: “Combination therapies for neurological disorders”.
